134 related articles for article (PubMed ID: 22273251)
1. Molecular monitoring 101: helping your patients with chronic myeloid leukemia to understand the meaning of molecular response.
Jabbour EJ; Quintás-Cardama A
Leuk Lymphoma; 2012 Aug; 53(8):1452-60. PubMed ID: 22273251
[TBL] [Abstract][Full Text] [Related]
2. Measuring minimal residual disease in chronic myeloid leukemia: fluorescence in situ hybridization and polymerase chain reaction.
Hughes TP; Branford S
Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S266-71. PubMed ID: 19778851
[TBL] [Abstract][Full Text] [Related]
3. Measurement of BCR-ABL1 transcripts on the International Scale in the United States: current status and best practices.
Arora R; Press RD
Leuk Lymphoma; 2017 Jan; 58(1):8-16. PubMed ID: 27412040
[TBL] [Abstract][Full Text] [Related]
4. A new highly sensitive real-time quantitative-PCR method for detection of BCR-ABL1 to monitor minimal residual disease in chronic myeloid leukemia after discontinuation of imatinib.
Kitamura H; Tabe Y; Ai T; Tsuchiya K; Yuri M; Misawa S; Horii T; Kawaguchi A; Ohsaka A; Kimura S
PLoS One; 2019; 14(3):e0207170. PubMed ID: 30835732
[TBL] [Abstract][Full Text] [Related]
5. Programme for Harmonization to the International Scale in Latin America for BCR-ABL1 quantification in CML patients: findings and recommendations.
Ruiz MS; Sánchez MB; Vera Contreras YM; Agrielo E; Alonso M; Altuna ME; Anchordoqui MS; Asinari M; Bonetto ME; Camargo M; Giere I; González J; Granda Alacote AC; Guerra J; Gutiérrez M; Maldonado C; Makiya R; Manrique G; Monaco ME; Rozo JC; Santamaría C; Seravalle A; Zea O; Zubillaga MN; Mordoh J; Larripa I; Bianchini M
Clin Chem Lab Med; 2020 Nov; 58(12):2025-2035. PubMed ID: 32374276
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Droplet Digital PCR versus qPCR Measurements on the International Scale for the Molecular Monitoring of Chronic Myeloid Leukemia Patients.
Cortés AA; Olmedillas S; Serrano-López J; Lainez-González D; Castaño T; Iñiguez R; Lopez-Lorenzo JL; García A; Atance M; Sánchez RNS; Lopez CB; Arranz MG; Sillero PL; Alonso-Dominguez JM
Mol Diagn Ther; 2020 Oct; 24(5):593-600. PubMed ID: 32875515
[TBL] [Abstract][Full Text] [Related]
7. Assessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative network.
Schäfer V; White HE; Gerrard G; Möbius S; Saussele S; Franke GN; Mahon FX; Talmaci R; Colomer D; Soverini S; Machova Polakova K; Cross NCP; Hochhaus A; Ernst T
J Cancer Res Clin Oncol; 2021 Oct; 147(10):3081-3089. PubMed ID: 33677711
[TBL] [Abstract][Full Text] [Related]
8. Comparison of BCR-ABL1 quantification in peripheral blood and bone marrow using an International Scale-standardized assay for assessment of deep molecular response in chronic myeloid leukemia.
Greiner G; Ratzinger F; Gurbisz M; Witzeneder N; Taghizadeh H; Mustafa SGK; Mitterbauer-Hohendanner G; Esterbauer H; Mannhalter C; Sperr WR; Valent P; Hoermann G
Clin Chem Lab Med; 2020 Jul; 58(8):1214-1222. PubMed ID: 32084002
[TBL] [Abstract][Full Text] [Related]
9. Analytical Validation of a Highly Sensitive, Multiplexed Chronic Myeloid Leukemia Monitoring System Targeting BCR-ABL1 RNA.
Brown JT; Beldorth IJ; Laosinchai-Wolf W; Fahey ME; Jefferson KL; Ruskin AK; Roth JJ; Cai L; Watt CD; Press RD; Yang F; Hedges JB; Andruss BF
J Mol Diagn; 2019 Jul; 21(4):718-733. PubMed ID: 31026597
[TBL] [Abstract][Full Text] [Related]
10. BCR-ABL1 RT-qPCR for monitoring the molecular response to tyrosine kinase inhibitors in chronic myeloid leukemia.
Press RD; Kamel-Reid S; Ang D
J Mol Diagn; 2013 Sep; 15(5):565-76. PubMed ID: 23810242
[TBL] [Abstract][Full Text] [Related]
11. Detection of
Uzoma IC; Taiwo IA; Nna EO; Durosinmi MA; Ukaejiofo EO
Niger J Clin Pract; 2019 Jan; 22(1):51-55. PubMed ID: 30666020
[TBL] [Abstract][Full Text] [Related]
12. Frequency of rare BCR-ABL1 fusion transcripts in chronic myeloid leukemia patients.
Arun AK; Senthamizhselvi A; Mani S; Vinodhini K; Janet NB; Lakshmi KM; Abraham A; George B; Srivastava A; Srivastava VM; Mathews V; Balasubramanian P
Int J Lab Hematol; 2017 Jun; 39(3):235-242. PubMed ID: 28035733
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic performance of the molecular BCR-ABL1 monitoring system may impact on inclusion of CML patients in stopping trials.
Spiess B; Rinaldetti S; Naumann N; Galuschek N; Kossak-Roth U; Wuchter P; Tarnopolscaia I; Rose D; Voskanyan A; Fabarius A; Hofmann WK; Saußele S; Seifarth W
PLoS One; 2019; 14(3):e0214305. PubMed ID: 30897165
[TBL] [Abstract][Full Text] [Related]
14. A BCR-ABL1 cutoff of 1.5% at 3 months, determined by the GeneXpert system, predicts an optimal response in patients with chronic myeloid leukemia.
García-Gutiérrez V; Gómez-Casares MT; Puerta JM; Alonso-Domínguez JM; Osorio S; Hernández-Boluda JC; Collado R; Ramírez MJ; Ibáñez F; Martín ML; Rodríguez-Gambarte JD; Martínez-Laperche C; Gómez M; Fiallo DV; Redondo S; Rodríguez A; Ruiz-Nuño C; Steegmann JL; Jiménez-Velasco A;
PLoS One; 2017; 12(3):e0173532. PubMed ID: 28278193
[TBL] [Abstract][Full Text] [Related]
15. BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome.
Elias MH; Baba AA; Azlan H; Rosline H; Sim GA; Padmini M; Fadilah SA; Ankathil R
Leuk Res; 2014 Apr; 38(4):454-9. PubMed ID: 24456693
[TBL] [Abstract][Full Text] [Related]
16. Molecular monitoring and mutations in chronic myeloid leukemia: how to get the most out of your tyrosine kinase inhibitor.
Baccarani M; Soverini S; De Benedittis C
Am Soc Clin Oncol Educ Book; 2014; ():167-75. PubMed ID: 24857074
[TBL] [Abstract][Full Text] [Related]
17. Clinical implications of conventional cytogenetics, fluorescence in situ hybridization (FISH) and molecular testing in chronic myeloid leukaemia patients in the tyrosine kinase inhibitor era - A review.
Ankathil R; Ismail SM; Mohd Yunus N; Sulong S; Husin A; Abdullah AD; Hassan R
Malays J Pathol; 2020 Dec; 42(3):307-321. PubMed ID: 33361712
[TBL] [Abstract][Full Text] [Related]
18. A review of the challenge in measuring and standardizing BCR-ABL1.
Yu S; Cui M; He X; Jing R; Wang H
Clin Chem Lab Med; 2017 Aug; 55(10):1465-1473. PubMed ID: 28222016
[TBL] [Abstract][Full Text] [Related]
19. RT-qPCR and RT-Digital PCR: A Comparison of Different Platforms for the Evaluation of Residual Disease in Chronic Myeloid Leukemia.
Alikian M; Whale AS; Akiki S; Piechocki K; Torrado C; Myint T; Cowen S; Griffiths M; Reid AG; Apperley J; White H; Huggett JF; Foroni L
Clin Chem; 2017 Feb; 63(2):525-531. PubMed ID: 27979961
[TBL] [Abstract][Full Text] [Related]
20. BCR-ABL1 kinase domain mutation analysis in an Irish cohort of chronic myeloid leukemia patients.
McCarron SL; O'Connor LM; Langabeer SE; Conneally E
Genet Test Mol Biomarkers; 2013 Feb; 17(2):170-3. PubMed ID: 23289634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
